newsfilter
← Latest News
GlobeNewswire·

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2